Cargando…

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the che...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosna, Federico, Capelli, Debora, Gottardi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483867/
https://www.ncbi.nlm.nih.gov/pubmed/28587190
http://dx.doi.org/10.3390/jcm6060057
_version_ 1783245794382446592
author Mosna, Federico
Capelli, Debora
Gottardi, Michele
author_facet Mosna, Federico
Capelli, Debora
Gottardi, Michele
author_sort Mosna, Federico
collection PubMed
description Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still hampering the spread of these techniques outside controlled clinical trials. We will also briefly speculate on future developments and offer our point of view, and a word of caution, on the present use of minimal residual disease measurements in “real-life” practice. Still, as final standardization and diffusion of the methods are sorted out, we believe that minimal residual disease will soon become the new standard for evaluating response in the treatment of acute myeloid leukemia.
format Online
Article
Text
id pubmed-5483867
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54838672017-06-28 Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? Mosna, Federico Capelli, Debora Gottardi, Michele J Clin Med Review Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still hampering the spread of these techniques outside controlled clinical trials. We will also briefly speculate on future developments and offer our point of view, and a word of caution, on the present use of minimal residual disease measurements in “real-life” practice. Still, as final standardization and diffusion of the methods are sorted out, we believe that minimal residual disease will soon become the new standard for evaluating response in the treatment of acute myeloid leukemia. MDPI 2017-06-03 /pmc/articles/PMC5483867/ /pubmed/28587190 http://dx.doi.org/10.3390/jcm6060057 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mosna, Federico
Capelli, Debora
Gottardi, Michele
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title_full Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title_fullStr Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title_full_unstemmed Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title_short Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
title_sort minimal residual disease in acute myeloid leukemia: still a work in progress?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483867/
https://www.ncbi.nlm.nih.gov/pubmed/28587190
http://dx.doi.org/10.3390/jcm6060057
work_keys_str_mv AT mosnafederico minimalresidualdiseaseinacutemyeloidleukemiastillaworkinprogress
AT capellidebora minimalresidualdiseaseinacutemyeloidleukemiastillaworkinprogress
AT gottardimichele minimalresidualdiseaseinacutemyeloidleukemiastillaworkinprogress